Buparlisib (BUP) or placebo (PBO) plus fulvestrant (FUL) in postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Overall survival (OS) results from BELLE-2, a randomized, phase III study

被引：0
|
作者：
Campone, Mario
Im, Seock-Ah
Iwata, Hiroji
Clemons, Mark
Ito, Yoshinori
Awada, Ahmad
Chia, Stephen
Jagiello-Gruszfeld, Agnieszka
Pistilli, Barbara
Tseng, Ling-Ming
Hurvitz, Sara
Masuda, Norikazu
Cortes, Javier
De laurentiis, Michele
Arteaga, Carlos L.
Jiang, Zefei
Jonat, Walter
Sellami, Dalila
El-Hashimy, Mona
Le Mouhaer, Sylvie
Sankaran, Banu
Bourdeau, Laurence
Baselga, Jose
机构：
[1] Ctr Rene Gauducheau, Inst Cancerol, Ouest Site, St Herblain, France
[2] Seoul Natl Univ, Coll Med, Seoul, South Korea
[3] Aichi Canc Ctr, Nagoya, Aichi, Japan
[4] Ottawa Hosp, Res Inst, Ottawa, ON, Canada
[5] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[6] Inst Jules Bordet, Brussels, Belgium
[7] BC Canc Agcy, Vancouver, BC, Canada
[8] Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland
[9] Inst Gustave Roussy, Villejuif, France
[10] Taipei Vet Gen Hosp, Taipei, Taiwan
[11] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA
[12] Natl Hosp Org Osaka Natl Hosp, Osaka, Japan
[13] Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[14] Fdn G Pascale, Ist Nazl Tumori, Naples, Italy
[15] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[16] PLA, Beijing Hosp 307, Beijing, Peoples R China
[17] Univ Hosp Schleswig Holstein, Kiel, Germany
[18] Novartis Pharmaceut, E Hanover, NJ USA
[19] Novartis Pharmaceut, Florham Pk, NJ USA
[20] Novartis Pharma SAS, Paris, France
[21] Novartis Inst BioMed Res, Cambridge, MA USA
[22] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD5-12
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Health-related quality of life (HRQoL) of postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) treated with ribociclib plus letrozole: Results from MONALEESA-2.
    Verma, Sunil
    O'Shaughnessy, Joyce
    Burris, Howard A.
    Campone, Mario
    Alba, Emilio
    Chandiwana, David
    Manson, Stephanie
    Sutradhar, Santosh C.
    Monaco, Mauricio
    Janni, Wolfgang
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Ribociclib plus letrozole for first-line treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): efficacy by baseline tumor markers
    Andre, Fabrice
    Stemmer, Salomon M.
    Campone, Mario
    Petrakova, Katarina
    Paluch-Shimon, Shani
    Yap, Yoon-Sim
    Marschner, Norbert
    Chan, Arlene
    Villanueva, Cristian
    Hart, Lowell L.
    Arteaga, Carlos L.
    Sonke, Gabe S.
    Grischke, Eva-Maria
    Alba, Emilio
    Nusch, Arnd
    Yardley, Denise A.
    Jakobsen, Erik
    Blau, Sibel
    Tolaney, Sara M.
    Su, Faye
    He, Wei
    Germa, Caroline
    Hortobagyi, Gabriel N.
    CANCER RESEARCH, 2017, 77
  • [23] THE ALPELISIB (ALP) EXPERIENCE IN THE SOLAR-1 AND BYLIEVE STUDIES: PERSPECTIVES FOR PRACTITIONERS CARING FOR PATIENTS (PTS) WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER (ABC)
    Rugo, Hope S.
    Andre, Fabrice
    Park, Yeon Hee
    Drullinsky, Pamela
    Loibl, Sibylle
    Cardoso, Fatima
    Mason, Ginny
    Aubel, Dawn
    Lorenzo, Ines
    Akdere, Murat
    Ciruelos, Eva M.
    BREAST, 2021, 59 : S49 - S49
  • [24] Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) from the CompLEEment-1 trial
    Campone, M.
    De laurentiis, M.
    Zamagni, C.
    Kudryavcev, I.
    Agterof, M.
    Brown-Glaberman, U.
    Palacova, M.
    Chatterjee, S.
    Menon-Singh, L.
    Wu, J.
    Zhou, K.
    Martin, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [25] Exploratory analysis of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER-2) PIK3CA mutated (mut) advanced breast cancer (aBC) treated with taselisib (TAS) and/or fulvestrant (FUL) reveals increased CCNE2 expression with poor outcome to placebo (PBO) plus FUL but not TAS plus FUL in SANDPIPER
    Johnson, Radia M.
    Liu, Bonnie
    Cortes, Javier
    Dent, Susan
    Harbeck, Nadia
    Krop, Ian E.
    Jacot, William
    Yauch, Robert L.
    Stout, Thomas J.
    Schimmoller, Frauke
    Gendreau, Steven
    Wilson, Timothy R.
    CANCER RESEARCH, 2023, 83 (07)
  • [26] NATALEE: Phase III study of ribociclib (RIBO) plus endocrine therapy (ET) as adjuvant treatment in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) early breast cancer (EBC).
    Slamon, Dennis J.
    Fasching, Peter A.
    Patel, Ravindranath
    Verma, Sunil
    Hurvitz, Sara A.
    Chia, Stephen K. L.
    Crown, John
    Martin, Miguel
    Barrios, Carlos H.
    Spera, Gonzalo
    Lopez, Celine
    Hor, Ines
    Pelov, Diana
    Hughes, Gareth
    Nawinne, Moditha
    Hortobagyi, Gabriel N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy (SOLAR-1)
    Andre, F.
    Kaufman, B.
    Juric, D.
    Ciruelos, E.
    Iwata, H.
    Mayer, I. A.
    Conte, P.
    Rugo, H. S.
    Loibl, S.
    Rubovszky, G.
    Tesch, H.
    Inoue, K.
    Lu, Y-S.
    Ryvo, L.
    Longin, A-S.
    Mills, D.
    Wilke, C.
    Germa, C.
    Campone, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] SOLAR-1: A phase III study of alpelisib and fulvestrant in men and postmenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC) progressing on or after aromatase inhibitor (AI) therapy
    Andre, F.
    Kaufman, B.
    Juric, D.
    Ciruelos, E. M.
    Iwata, H.
    Mayer, I. A.
    Rugo, H. S.
    Conte, P.
    Liobl, S.
    Rubovszky, G.
    Inoue, K.
    Tesch, H.
    Lu, Y-S
    Ryvo, L.
    Longin, A-S
    Mills, D.
    Wilke, C.
    Germa, C.
    Campone, M.
    CANCER RESEARCH, 2017, 77
  • [29] Prognostic factors for overall survival (OS) in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (HR+/HER2-ABC): Analyses from PALOMA-3
    Rugo, H. S.
    Cristofanilli, M.
    Loibl, S.
    Harbeck, N.
    DeMichele, A.
    Iwata, H.
    Park, Y. H.
    Brufsky, A.
    Theall, K. Puyana
    Huang, X.
    Mcroy, L.
    Bananis, E.
    Turner, N. C.
    ANNALS OF ONCOLOGY, 2020, 31 : S372 - S373
  • [30] Ribociclib plus endocrine therapy (ET) doublet combinations in hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Phase I clinical activity and impact of molecular alterations
    Julie, Dejan
    Campone, Mario
    Munster, Pamela
    Ismail-Khan, Roohi
    Estevez, Laura Garcia
    Chavez-MacGregor, Mariana
    Frassoldati, Antonio
    Hui, Rina
    Mayer, Ingrid A.
    Cortes, Javier
    Goncalves, Anthony
    De Boer, Richard H.
    Dirix, Luc
    Tolaney, Sara M.
    Lee, Soo Chin
    Maur, Michela
    Wang, Yingbo
    Su, Faye
    Dobson, Jason R.
    Germa, Caroline
    Hewes, Becker
    Bardia, Aditya
    CANCER RESEARCH, 2017, 77
12345